Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, Kaji H, Shinoda T, Hisanaga S, Ueda K. (Jan 2002). “Tubulin seeds alpha-synuclein fibril formation.”. J. Biol. Chem.277 (3): 2112?7. doi:10.1074/jbc.M102981200. PMID11698390.
Beyer K (September 2006). “Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers”. Acta Neuropathol.112 (3): 237?51. doi:10.1007/s00401-006-0104-6. PMID16845533.
Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T (February 1995). “The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system”. Neuron14 (2): 467?75. doi:10.1016/0896-6273(95)90302-X. PMID7857654.
Yu S, Li X, Liu G, Han J, Zhang C, Li Y, Xu S, Liu C, Gao Y, Yang H, Uéda K, Chan P (March 2007). “Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody”. Neuroscience145 (2): 539?55. doi:10.1016/j.neuroscience.2006.12.028. PMID17275196.
Zhang L, Zhang C, Zhu Y, Cai Q, Chan P, Uéda K, Yu S, Yang H (December 2008). “Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody”. Brain Res1244: 40?52. doi:10.1016/j.brainres.2008.08.067. PMID18817762.
Liu G, Zhang C, Yin J, Li X, Cheng F, Li Y, Yang H, Uéda K, Chan P, Yu S (May 2009). “Alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity”. Neurosci. Lett.454 (3): 187?92. doi:10.1016/j.neulet.2009.02.056. PMID19429081.
Uéda K, Saitoh T, Mori H (December 1994). “Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid.”. Biochem. Biophys. Res. Commun.205 (2): 1366?72. doi:10.1006/bbrc.1994.2816. PMID7802671.
George JM, Jin H, Woods WS, Clayton DF (August 1995). “Characterization of a novel protein regulated during the critical period for song learning in the zebra finch”. Neuron15 (2): 361?72. doi:10.1016/0896-6273(95)90040-3. PMID7646890.
Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ (December 2003). “Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein”. Science302 (5651): 1769?72. doi:10.1126/science.1090389. PMID14657499.
Zhu M, Li J, Fink AL (October 2003). “The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation”. J. Biol. Chem.278 (41): 40186?97. doi:10.1074/jbc.M305326200. PMID12885775.
Madine J, Doig AJ, Middleton DA (May 2006). “A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers”. Biochemistry45 (18): 5783?92. doi:10.1021/bi052151q. PMID16669622.
Zhu M, Qin ZJ, Hu D, Munishkina LA, Fink AL (July 2006). “Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles”. Biochemistry45 (26): 8135?42. doi:10.1021/bi052584t. PMID16800638.
Clayton D.F. and George J.M. (1998). “The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease”. Trends in Neuroscience21 (6): 249?254. doi:10.1016/S0166-2236(97)01213-7.
Bartels T, Choi JG, Selkoe DJ (August 2011). “α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation”. Nature477 (7362). doi:10.1038/nature10324. PMID21841800. 非専門家向けの内容要旨 – Harvard Medical School New Focus.
Arima K, Uéda K, Sunohara N, Hirai S, Izumiyama Y, Tonozuka-Uehara H, Kawai M (October 1998). “Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies”. Brain Res.808 (1): 93?100. doi:10.1016/S0006-8993(98)00734-3. PMID9795161.
Arima K, Uéda K, Sunohara N, Arakawa K, Hirai S, Nakamura M, Tonozuka-Uehara H, Kawai M (November 1998). “NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy”. Acta Neuropathol.96 (5): 439?44. doi:10.1007/s004010050917. PMID9829806.
Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Uéda K, Ikeda K, Kawai M (October 1999). “Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies”. Brain Res.843 (1): 53?61. doi:10.1016/S0006-8993(99)01848-X. PMID10528110.
Arima K, Mizutani T, Alim MA, Tonozuka-Uehara H, Izumiyama Y, Hirai S, Ueda K (August 2000). “NACP/alpha-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies”. Acta Neuropathol.100 (2): 115?21. doi:10.1007/s004010050002. PMID10963357.
Yokota O, Terada S, Ishizu H, Ujike H, Ishihara T, Nakashima H, Yasuda M, Kitamura Y, Uéda K, Checler F, Kuroda S (December 2002). “NACP/alpha-synuclein, NAC, and beta-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases”. Acta Neuropathol.104 (6): 637?48. doi:10.1007/s00401-002-0596-7. PMID12410385.
Kim HY, Heise H, Fernandez CO, Baldus M, Zweckstetter M (September 2007). “Correlation of amyloid fibril beta-structure with the unfolded state of alpha-synuclein”. Chembiochem8 (14): 1671?4. doi:10.1002/cbic.200700366. PMID17722123.
Li J, Uversky VN, Fink AL (September 2001). “Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein”. Biochemistry40 (38): 11604?13. doi:10.1021/bi010616g. PMID11560511.
Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, Llorens V, Gomez Tortosa E, del Ser T, Muñoz DG, de Yebenes JG (February 2004). “The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia”. Ann. Neurol.55 (2): 164?73. doi:10.1002/ana.10795. PMID14755719.
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (October 2003). “alpha-Synuclein locus triplication causes Parkinson's disease”. Science302 (5646): 841. doi:10.1126/science.1090278. PMID14593171.
Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Masliah E (March 2000). “C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders”. Acta Neuropathol.99 (3): 296?304. doi:10.1007/PL00007441. PMID10663973.
Wersinger C, Sidhu A (April 2003). “Attenuation of dopamine transporter activity by alpha-synuclein”. Neurosci. Lett.340 (3): 189?92. doi:10.1016/S0304-3940(03)00097-1. PMID12672538.
Lee FJ, Liu F, Pristupa ZB, Niznik HB (April 2001). “Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis”. FASEB J.15 (6): 916?26. doi:10.1096/fj.00-0334com. PMID11292651.
Kawahara K, Hashimoto M, Bar-On P, Ho GJ, Crews L, Mizuno H, Rockenstein E, Imam SZ, Masliah E (March 2008). “alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease”. J. Biol. Chem.283 (11): 6979?87. doi:10.1074/jbc.M710418200. PMID18195004.
Ahn BH, Rhim H, Kim SY, Sung YM, Lee MY, Choi JY, Wolozin B, Chang JS, Lee YH, Kwon TK, Chung KC, Yoon SH, Hahn SJ, Kim MS, Jo YH, Min DS (April 2002). “alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells”. J. Biol. Chem.277 (14): 12334?42. doi:10.1074/jbc.M110414200. PMID11821392.
Neystat M, Rzhetskaya M, Kholodilov N, Burke RE (June 2002). “Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay”. Neurosci. Lett.325 (2): 119?23. doi:10.1016/S0304-3940(02)00253-7. PMID12044636.
Kawamata H, McLean PJ, Sharma N, Hyman BT (May 2001). “Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations”. J. Neurochem.77 (3): 929?34. doi:10.1046/j.1471-4159.2001.00301.x. PMID11331421.
Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ, Margolis RL, Troncoso JC, Lanahan AA, Worley PF, Dawson VL, Dawson TM, Ross CA (May 1999). “Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions”. Nat. Genet.22 (1): 110?4. doi:10.1038/8820. PMID10319874.
Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R (September 1999). “alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356”. J. Biol. Chem.274 (36): 25481?9. doi:10.1074/jbc.274.36.25481. PMID10464279.
Giasson BI, Lee VM, Trojanowski JQ (2003). “Interactions of amyloidogenic proteins”. Neuromolecular Med.4 (1-2): 49?58. doi:10.1385/NMM:4:1-2:49. PMID14528052.
Bartels T, Choi JG, Selkoe DJ (August 2011). “α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation”. Nature477 (7362). doi:10.1038/nature10324. PMID21841800. 非専門家向けの内容要旨 – Harvard Medical School New Focus.
Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, Kaji H, Shinoda T, Hisanaga S, Ueda K. (Jan 2002). “Tubulin seeds alpha-synuclein fibril formation.”. J. Biol. Chem.277 (3): 2112?7. doi:10.1074/jbc.M102981200. PMID11698390.
Beyer K (September 2006). “Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers”. Acta Neuropathol.112 (3): 237?51. doi:10.1007/s00401-006-0104-6. PMID16845533.
Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T (February 1995). “The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system”. Neuron14 (2): 467?75. doi:10.1016/0896-6273(95)90302-X. PMID7857654.
Mori, F; Tanji, K; Yoshimoto, M; Takahashi, H; Wakabayashi, K (Jul 2002). “Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment”. Exp Neurol176 (1): 98-104. PMID12093086.
Yu S, Li X, Liu G, Han J, Zhang C, Li Y, Xu S, Liu C, Gao Y, Yang H, Uéda K, Chan P (March 2007). “Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody”. Neuroscience145 (2): 539?55. doi:10.1016/j.neuroscience.2006.12.028. PMID17275196.
Zhang L, Zhang C, Zhu Y, Cai Q, Chan P, Uéda K, Yu S, Yang H (December 2008). “Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody”. Brain Res1244: 40?52. doi:10.1016/j.brainres.2008.08.067. PMID18817762.
Liu G, Zhang C, Yin J, Li X, Cheng F, Li Y, Yang H, Uéda K, Chan P, Yu S (May 2009). “Alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity”. Neurosci. Lett.454 (3): 187?92. doi:10.1016/j.neulet.2009.02.056. PMID19429081.
Uéda K, Saitoh T, Mori H (December 1994). “Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid.”. Biochem. Biophys. Res. Commun.205 (2): 1366?72. doi:10.1006/bbrc.1994.2816. PMID7802671.
George JM, Jin H, Woods WS, Clayton DF (August 1995). “Characterization of a novel protein regulated during the critical period for song learning in the zebra finch”. Neuron15 (2): 361?72. doi:10.1016/0896-6273(95)90040-3. PMID7646890.
Alim MA, Ma QL, Takeda K, Aizawa T, Matsubara M, Nakamura M, Asada A, Saito T, Kaji H, Yoshii M, Hisanaga S, Ueda K (August 2004). “Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein”. J. Alzheimers Dis.6 (4): 435?42; discussion 443?9. PMID15345814.
Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ (December 2003). “Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein”. Science302 (5651): 1769?72. doi:10.1126/science.1090389. PMID14657499.
Zhu M, Li J, Fink AL (October 2003). “The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation”. J. Biol. Chem.278 (41): 40186?97. doi:10.1074/jbc.M305326200. PMID12885775.
Madine J, Doig AJ, Middleton DA (May 2006). “A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers”. Biochemistry45 (18): 5783?92. doi:10.1021/bi052151q. PMID16669622.
Zhu M, Qin ZJ, Hu D, Munishkina LA, Fink AL (July 2006). “Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles”. Biochemistry45 (26): 8135?42. doi:10.1021/bi052584t. PMID16800638.
Bartels T, Choi JG, Selkoe DJ (August 2011). “α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation”. Nature477 (7362). doi:10.1038/nature10324. PMID21841800. 非専門家向けの内容要旨 – Harvard Medical School New Focus.
Arima K, Uéda K, Sunohara N, Hirai S, Izumiyama Y, Tonozuka-Uehara H, Kawai M (October 1998). “Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies”. Brain Res.808 (1): 93?100. doi:10.1016/S0006-8993(98)00734-3. PMID9795161.
Arima K, Uéda K, Sunohara N, Arakawa K, Hirai S, Nakamura M, Tonozuka-Uehara H, Kawai M (November 1998). “NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy”. Acta Neuropathol.96 (5): 439?44. doi:10.1007/s004010050917. PMID9829806.
Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Uéda K, Ikeda K, Kawai M (October 1999). “Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies”. Brain Res.843 (1): 53?61. doi:10.1016/S0006-8993(99)01848-X. PMID10528110.
Arima K, Mizutani T, Alim MA, Tonozuka-Uehara H, Izumiyama Y, Hirai S, Ueda K (August 2000). “NACP/alpha-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies”. Acta Neuropathol.100 (2): 115?21. doi:10.1007/s004010050002. PMID10963357.
Yokota O, Terada S, Ishizu H, Ujike H, Ishihara T, Nakashima H, Yasuda M, Kitamura Y, Uéda K, Checler F, Kuroda S (December 2002). “NACP/alpha-synuclein, NAC, and beta-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases”. Acta Neuropathol.104 (6): 637?48. doi:10.1007/s00401-002-0596-7. PMID12410385.
Kim HY, Heise H, Fernandez CO, Baldus M, Zweckstetter M (September 2007). “Correlation of amyloid fibril beta-structure with the unfolded state of alpha-synuclein”. Chembiochem8 (14): 1671?4. doi:10.1002/cbic.200700366. PMID17722123.
Woulfe J, Hoogendoorn H, Tarnopolsky M, Muñoz DG. (Nov14). “Monoclonal antibodies against Epstein-Barr virus cross-react with alpha-synuclein in human brain.”. Neurology55 (9): 1398-1401. PMID11087792.
Li J, Uversky VN, Fink AL (September 2001). “Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein”. Biochemistry40 (38): 11604?13. doi:10.1021/bi010616g. PMID11560511.
Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, Llorens V, Gomez Tortosa E, del Ser T, Muñoz DG, de Yebenes JG (February 2004). “The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia”. Ann. Neurol.55 (2): 164?73. doi:10.1002/ana.10795. PMID14755719.
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (October 2003). “alpha-Synuclein locus triplication causes Parkinson's disease”. Science302 (5646): 841. doi:10.1126/science.1090278. PMID14593171.
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (Feb 2002). “alpha-Synuclein is phosphorylated in synucleinopathy lesions”. Nat Cell Biol4 (2): 160-164. PMID11813001.
Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Masliah E (March 2000). “C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders”. Acta Neuropathol.99 (3): 296?304. doi:10.1007/PL00007441. PMID10663973.
Wersinger C, Sidhu A (April 2003). “Attenuation of dopamine transporter activity by alpha-synuclein”. Neurosci. Lett.340 (3): 189?92. doi:10.1016/S0304-3940(03)00097-1. PMID12672538.
Lee FJ, Liu F, Pristupa ZB, Niznik HB (April 2001). “Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis”. FASEB J.15 (6): 916?26. doi:10.1096/fj.00-0334com. PMID11292651.
Choi P, Golts N, Snyder H, Chong M, Petrucelli L, Hardy J, Sparkman D, Cochran E, Lee JM, Wolozin B (September 2001). “Co-association of parkin and alpha-synuclein”. NeuroReport12 (13): 2839?43. PMID11588587.
Kawahara K, Hashimoto M, Bar-On P, Ho GJ, Crews L, Mizuno H, Rockenstein E, Imam SZ, Masliah E (March 2008). “alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease”. J. Biol. Chem.283 (11): 6979?87. doi:10.1074/jbc.M710418200. PMID18195004.
Ahn BH, Rhim H, Kim SY, Sung YM, Lee MY, Choi JY, Wolozin B, Chang JS, Lee YH, Kwon TK, Chung KC, Yoon SH, Hahn SJ, Kim MS, Jo YH, Min DS (April 2002). “alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells”. J. Biol. Chem.277 (14): 12334?42. doi:10.1074/jbc.M110414200. PMID11821392.
Neystat M, Rzhetskaya M, Kholodilov N, Burke RE (June 2002). “Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay”. Neurosci. Lett.325 (2): 119?23. doi:10.1016/S0304-3940(02)00253-7. PMID12044636.
Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, Pleasure D (December 1991). “Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin”. Cancer Res.51 (24): 6529?38. PMID1742726.
Kawamata H, McLean PJ, Sharma N, Hyman BT (May 2001). “Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations”. J. Neurochem.77 (3): 929?34. doi:10.1046/j.1471-4159.2001.00301.x. PMID11331421.
Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ, Margolis RL, Troncoso JC, Lanahan AA, Worley PF, Dawson VL, Dawson TM, Ross CA (May 1999). “Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions”. Nat. Genet.22 (1): 110?4. doi:10.1038/8820. PMID10319874.
Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R (September 1999). “alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356”. J. Biol. Chem.274 (36): 25481?9. doi:10.1074/jbc.274.36.25481. PMID10464279.
Giasson BI, Lee VM, Trojanowski JQ (2003). “Interactions of amyloidogenic proteins”. Neuromolecular Med.4 (1-2): 49?58. doi:10.1385/NMM:4:1-2:49. PMID14528052.
